دورية أكاديمية
Panobinostat and Multiple Myeloma in 2018
| العنوان: | Panobinostat and Multiple Myeloma in 2018 |
|---|---|
| المؤلفون: | Yee, Andrew J., Raje, Noopur S. |
| بيانات النشر: | AlphaMed Press |
| سنة النشر: | 2018 |
| المجموعة: | Harvard University: DASH - Digital Access to Scholarship at Harvard |
| الوصف: | FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class. ; Version of Record |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947458/pdfTest/; The Oncologist; Yee, Andrew J., and Noopur S. Raje. 2018. “Panobinostat and Multiple Myeloma in 2018.” The Oncologist 23 (5): 516-517. doi:10.1634/theoncologist.2017-0644. http://dx.doi.org/10.1634/theoncologist.2017-0644Test.; http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160277Test |
| DOI: | 10.1634/theoncologist.2017-0644 |
| الإتاحة: | https://doi.org/10.1634/theoncologist.2017-0644Test http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160277Test |
| رقم الانضمام: | edsbas.4A9EB60B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1634/theoncologist.2017-0644 |
|---|